Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)

No­var­tis ax­es a once 'first-in-class' prospect as an­oth­er JAK pro­gram fails to clear a risk/ben­e­fit analy­sis

The JAK class can count one more clin­i­cal fail­ure, the lat­est in a long string of set­backs that con­tin­ues to cloud the fu­ture of these ther­a­pies.

In its Q4 up­date to­day phar­ma gi­ant No­var­tis not­ed that it has swept out a pan-JAK pro­gram for CEE321. De­tails are scant, and the work was very much ear­ly-stage, but No­var­tis had held it up as a bright prospect be­fore for atopic der­mati­tis.

In their pipeline sum­ma­ry, the com­pa­ny not­ed that the pro­gram had been dis­con­tin­ued be­cause it had failed to clear the bar on risk/ben­e­fit.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.